{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:56:44Z","timestamp":1794581804376,"version":"4.9.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["metabolismjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.metabol.2024.156038","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T16:09:28Z","timestamp":1726762168000},"page":"156038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"161","author":[{"given":"Zeyu","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guimei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoru","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weishang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiling","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2024.156038_bb0005","series-title":"World obesity federation","year":"2024"},{"issue":"11","key":"10.1016\/j.metabol.2024.156038_bb0010","first-page":"909","article-title":"Current status and outlook of clinical research and practice of obesity in China [J]","volume":"39","author":"Shen","year":"2023","journal-title":"Chin J Endocrinol Metabol"},{"issue":"11","key":"10.1016\/j.metabol.2024.156038_bb0015","first-page":"1137","article-title":"Clinical consensus on multidisciplinary management of obesity (2021 edition) [J]","volume":"20","author":"Endocrinology Branch of Chinese Medical Association, Diabetes Branch of Chinese Society of Traditional Chinese Medicine, Obesity and Diabetes Surgery Committee of Chinese Physicians Association of Surgeons","year":"2021","journal-title":"Chinese Journal of Gastrointestinal Surgery"},{"key":"10.1016\/j.metabol.2024.156038_bb0020","doi-asserted-by":"crossref","first-page":"154388","DOI":"10.1016\/j.metabol.2020.154388","article-title":"Factors affecting weight loss variability in obesity","volume":"113","author":"Dent","year":"2020","journal-title":"Metabolism"},{"issue":"8","key":"10.1016\/j.metabol.2024.156038_bb0025","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.metabol.2016.04.004","article-title":"(2016). Pharmacological management of nonalcoholic fatty liver disease","volume":"65","author":"Barb","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156038_bb0030","doi-asserted-by":"crossref","first-page":"155741","DOI":"10.1016\/j.metabol.2023.155741","article-title":"Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond","volume":"151","author":"Tsilingiris","year":"2024","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.metabol.2024.156038_bb0035","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"(2021) Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u0131as","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156038_bb0040","series-title":"8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes\u20132024. Diabetes Care 1 January 2024; 47 (Supplement_1)","first-page":"S145","author":"American Diabetes Association Professional Practice Committee","year":"2024"},{"key":"10.1016\/j.metabol.2024.156038_bb0045","doi-asserted-by":"crossref","first-page":"101691","DOI":"10.1016\/j.eclinm.2022.101691","article-title":"Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial","volume":"54","author":"Ji","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.metabol.2024.156038_bb0050","doi-asserted-by":"crossref","first-page":"1156521","DOI":"10.3389\/fendo.2023.1156521","article-title":"Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial","volume":"14","author":"Wen","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.metabol.2024.156038_bb0055","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7570\/jomes23032","article-title":"Approved anti-obesity medications in 2022 KSSO guidelines and the promise of phase 3 clinical trials: anti-obesity drugs in the sky and on the horizon","volume":"32","author":"Jeon","year":"2023","journal-title":"J Obes Metab Syndr"},{"key":"10.1016\/j.metabol.2024.156038_bb0060","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2147\/CLEP.S391819","article-title":"Efficacy and safety of liraglutide and semaglutide on weight loss in people with obesity or overweight: a systematic review","volume":"14","author":"Xie","year":"2022","journal-title":"Clin Epidemiol"},{"issue":"10402","key":"10.1016\/j.metabol.2024.156038_bb0065","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.metabol.2024.156038_bb0070","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"SURMOUNT-1 investigators. Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156038_bb0075","author":"Rosenstock","year":"2021"},{"issue":"10160","key":"10.1016\/j.metabol.2024.156038_bb0080","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2024.156038_bb0085","doi-asserted-by":"crossref","unstructured":"Zhao L, Cheng Z, Lu Y, et al (2024) Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial. JAMA 2024 Aug 20;332(7):551\u2013560. doi:https:\/\/doi.org\/10.1001\/jama.2024.9217.","DOI":"10.1001\/jama.2024.9217"},{"issue":"2","key":"10.1016\/j.metabol.2024.156038_bb0090","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/dom.15360","article-title":"Beinaglutide for weight management in Chinese individuals with overweight or obesity: a phase 3 randomized controlled clinical study","volume":"26","author":"Chen","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.metabol.2024.156038_bb0095","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2337\/dc23-1287","article-title":"Efficacy and safety of Mazdutide in Chinese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial","volume":"47","author":"Zhang","year":"2024","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.metabol.2024.156038_bb0100","doi-asserted-by":"crossref","first-page":"8289","DOI":"10.1038\/s41467-023-44067-4","article-title":"A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity","volume":"14","author":"Ji","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2024.156038_bb0105","doi-asserted-by":"crossref","unstructured":"Linong Ji, Hongwei Jiang, Hua Li, et al.; 1856-LB: Efficacy and Safety of Mazdutide in Chinese Participants with Overweight or Obesity (GLORY-1). Diabetes 14 June 2024; 73 (Supplement_1): 1856\u2013LB. doi:https:\/\/doi.org\/10.2337\/db24-1856-LB.","DOI":"10.2337\/db24-1856-LB"},{"issue":"10","key":"10.1016\/j.metabol.2024.156038_bb0110","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist Orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156038_bb0115","author":"Frias","year":"2023"},{"issue":"6","key":"10.1016\/j.metabol.2024.156038_bb0120","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Retatrutide phase 2 obesity trial investigators. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"issue":"10401","key":"10.1016\/j.metabol.2024.156038_bb0125","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.metabol.2024.156038_bb0130","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S2213-8587(23)00388-1","article-title":"Efficacy and safety of once weekly semaglutide 2\u00b74 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial","volume":"12","author":"Mu","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.metabol.2024.156038_bb0135","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"issue":"384","key":"10.1016\/j.metabol.2024.156038_bb0140","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly Semaglutide in adults with overweight or obesity","volume":"2021","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.metabol.2024.156038_bb0145","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.metabol.2024.156038_bb0150","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous Semaglutide vs daily Liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.metabol.2024.156038_bb0155","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous Semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"10278","key":"10.1016\/j.metabol.2024.156038_bb0160","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.metabol.2024.156038_bb0165","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","article-title":"Efficacy and safety of once-weekly semaglutide 2.4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial","volume":"12","author":"McGowan","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.metabol.2024.156038_bb0170","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/oby.23481","article-title":"Effects of liraglutide on gastrointestinal functions and weight in obesity: a randomized clinical and pharmacogenomic trial","volume":"30","author":"Maselli","year":"2022","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"10.1016\/j.metabol.2024.156038_bb0175","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/oby.22726","article-title":"Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial","volume":"28","author":"Wadden","year":"2020","journal-title":"Obesity (Silver Spring)"},{"issue":"2","key":"10.1016\/j.metabol.2024.156038_bb0180","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.fertnstert.2022.04.027","article-title":"Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study","volume":"118","author":"Elkind-Hirsch","year":"2022","journal-title":"Fertil Steril"},{"issue":"1","key":"10.1016\/j.metabol.2024.156038_bb0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of Liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"9701","key":"10.1016\/j.metabol.2024.156038_bb0190","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.metabol.2024.156038_bb0195","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of Liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.metabol.2024.156038_bb0200","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with Tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.metabol.2024.156038_bb0205","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial[J]","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2024.156038_bb0210","doi-asserted-by":"crossref","unstructured":"Ahr\u00e9n B, Atkin SL, Charpentier G, et al (2018) Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes Obes Metab 2018 Sep;20(9):2210\u20132219. doi:https:\/\/doi.org\/10.1111\/dom.13353.","DOI":"10.1111\/dom.13353"},{"key":"10.1016\/j.metabol.2024.156038_bb0215","doi-asserted-by":"crossref","unstructured":"Bi Y, Lu S, Tang J, et al (2024) efficacy and safety of Tirzepatide in patients with type 2 diabetes: analysis of SURPASS-AP-combo by different subgroups. Diabetes Ther 2024 May;15(5):1125\u20131137. doi:https:\/\/doi.org\/10.1007\/s13300-024-01561-2.","DOI":"10.1007\/s13300-024-01561-2"},{"issue":"7","key":"10.1016\/j.metabol.2024.156038_bb0220","first-page":"545","article-title":"Guideline for chronic weight management and clinical practice of anti-obesity medications (2024 version) [J]","volume":"40","author":"Chinese Society of Endocrinology","year":"2024","journal-title":"Chin J Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.metabol.2024.156038_bb0225","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.ajcnut.2023.04.017","article-title":"The weight-loss effect of GLP-1RAs glucagon-like Peptide-1 receptor agonists in non-diabetic individuals with overweight or obesity: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials","volume":"118","author":"Liu","year":"2023","journal-title":"Am J Clin Nutr"},{"issue":"7","key":"10.1016\/j.metabol.2024.156038_bb0230","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/oby.24042","article-title":"Efficacy and safety of semaglutide 2.4mg by race and ethnicity: a post hoc analysis of three randomized controlled trials","volume":"32","author":"Rubino","year":"2024","journal-title":"Obesity (Silver Spring)"},{"issue":"4","key":"10.1016\/j.metabol.2024.156038_bb0235","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/dom.12632","article-title":"Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials","volume":"18","author":"Ard","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"64","key":"10.1016\/j.metabol.2024.156038_bb0240","doi-asserted-by":"crossref","first-page":"102181","DOI":"10.1016\/j.eclinm.2023.102181","article-title":"Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis","author":"Caruso","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.metabol.2024.156038_bb0245","doi-asserted-by":"crossref","first-page":"116150","DOI":"10.1016\/j.biopha.2024.116150","article-title":"Efficacy and safety of GLP-1RAs for people with obesity: a systematic review based on RCT and Bayesian network meta-analysis","volume":"171","author":"Li","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"10.1016\/j.metabol.2024.156038_bb0250","doi-asserted-by":"crossref","first-page":"e13543","DOI":"10.1111\/obr.13543","article-title":"Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials","volume":"24","author":"Alkhezi","year":"2023","journal-title":"Obes Rev"},{"key":"10.1016\/j.metabol.2024.156038_bb0255","series-title":"[Chinese guidelines for lipid management (2023)]. Zhonghua Xin Xue Guan Bing Za Zhi","author":"Joint Committee on the Chinese Guidelines for Lipid Management","year":"2023"},{"issue":"4","key":"10.1016\/j.metabol.2024.156038_bb0260","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.metabol.2024.156038_bb0265","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.metabol.2024.156038_bb0270","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specifed meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2024.156038_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","article-title":"Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics","volume":"267","author":"Nicholls","year":"2023","journal-title":"Am Heart J"},{"issue":"24","key":"10.1016\/j.metabol.2024.156038_bb0280","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes [J]","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. Med."},{"key":"10.1016\/j.metabol.2024.156038_bb0285","series-title":"Comparative efectiveness of semaglutide and tirzepatide for weight loss in adults with overweight and obesity in the US: a real-world evidence study. medRxiv 2023.11.21.23298775 (Preprint)","author":"Rodriguez","year":"2023"},{"issue":"06","key":"10.1016\/j.metabol.2024.156038_bb0290","first-page":"718","article-title":"Cost-utility analysis of 5 kinds of GLP-1RAs in the treatment of poorly controlled type 2 diabetes mellitus treated with metformin","volume":"35","author":"Xie","year":"2024","journal-title":"China Pharmacy"},{"issue":"4","key":"10.1016\/j.metabol.2024.156038_bb0295","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/dom.14940","article-title":"Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: a value for money analysis","volume":"25","author":"Azuri","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.metabol.2024.156038_bb0300","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1007\/s00125-023-05891-x","article-title":"Sex diferences in type 2 diabetes","volume":"66","author":"Kautzky-Willer","year":"2023","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.metabol.2024.156038_bb0305","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3390\/jpm12030454","article-title":"Sex differences in response to treatment with glucagon-like peptide 1 receptor agonists: opportunities for a tailored approach to diabetes and obesity care","volume":"12","author":"Rentzeperi","year":"2022","journal-title":"J Pers Med"},{"issue":"6","key":"10.1016\/j.metabol.2024.156038_bb0310","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11892-015-0602-9","article-title":"\u03b2 cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in east Asians","volume":"15","author":"Yabe","year":"2015","journal-title":"Curr Diab Rep"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002604952400266X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002604952400266X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T17:14:08Z","timestamp":1731690848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002604952400266X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":62,"alternative-id":["S002604952400266X"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2024.156038","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2024.156038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156038"}}